Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1LG2 | Q9BQ51 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.48 |
| ▸ | MME | P08473 | 2/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.38 |
| ▸ | BHMT | Q93088 | 1/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5053902 | 1.00 | PDCD1LG2 (0.48) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL8526147 | 1.00 | PDCD1LG2 (0.48) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL30462197 | 0.94 | PDCD1LG2 (0.44) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL29599569 | 0.89 | ENPEP (0.50) | ENPEP | |
| SCHEMBL29867109 | 0.89 | PDCD1LG2 (0.50) | PDCD1LG2CD274MMEVSIR | |
| SCHEMBL31319509 | 0.88 | OPRM1 (0.46) | PDCD1LG2CD274MME | |
| SCHEMBL8528144 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL29572257 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL29572216 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 | |
| SCHEMBL5998197 | 0.88 | CD274 (0.57) | PDCD1LG2CD274MMEDPP4DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743479-A1 | ADENOVIRUSES | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | claimed |
| EP-4743101-A1 | MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | claimed |
| WO-2025012636-A1 | MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER | THEOLYTICS LTD (GB) | 2025-01-16 | — | — | WO | claimed |
| WO-2025012637-A1 | ADENOVIRUSES | THEOLYTICS LTD (GB) | 2025-01-16 | — | — | WO | claimed |
| WO-2025002589-A1 | TISSUE EXTRACELLULAR PEPTIDE PATTERNS DEDICATED FOR GENERATION OF ANTI-CANCER VACCINES AGAINST SALIVARY GLAND TUMOR, IDENTIFICATION AND ISOLATION OF SALIVARY GLAND TUMOR SPECIFIC T CELLS IN HUMANS | Uniwersytet Gdański (PL) | 2025-01-02 | — | — | WO | claimed |
| US-20240391958-A1 | KEANUMYCINS AND USES THEREOF IN MEDICINE AND PLANT PROTECTION | LEIBNIZ-INSTITUT FÜR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E. V. HANS-KNÖLL-INSTITUT (HKI) (DE) | 2024-11-28 | — | — | US | claimed |
| CN-115047120-A | Dansyl chloride derivatization method for analyzing and detecting dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2022-09-13 | — | — | CN | claimed |
| WO-2022026633-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| EP-4746974-A1 | GP130 ANTIGEN-BINDING ANTIBODIES | VVB Bio Pte. Ltd. (SG) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107097-A1 | SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | ENLAZA THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| EP-4743101-A1 | MUTATED ADENOVIRUSES WITH IMPROVED REPLICATION AND THEIR USE FOR TREATING CANCER | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | disclosed |
| EP-4743479-A1 | ADENOVIRUSES | Theolytics Ltd. (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-12565666-B2 | Methods and compositions for modulating a genome | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20260047588-A1 | ANIMAL FEED ADDITIVES COMPRISING POLYPEPTIDE HAVING PROTEASE ACTIVITY AND USES THEREOF | NOVOZYMES A/S (DK) | 2026-02-19 | — | — | US | disclosed |
| CN-114096677-A | Industrial fermentation method of microbial cells using fed-batch pre-culture | 巴斯夫欧洲公司 | 2022-02-25 | — | — | CN | disclosed |
| WO-2022026633-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| WO-2022026631-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| EP-0885743-A1 | Assemblage for thermal dye transfer | EASTMAN KODAK COMPANY (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5786300-A | Assemblage for thermal dye transfer | EASTMAN KODAK COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| US-4001455-A | SWEETENING COMPOSITIONS | E. R. SQUIBB & SONS, INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260047588-A1 | ANIMAL FEED ADDITIVES COMPRISING POLYPEPTIDE HAVING PROTEASE ACTIVITY AND USES THEREOF | PREP, VIP, CTRL | PDCD1LG2 2729/4885CD274 3745/4885MME 44/4885 |
| US-20240391958-A1 | KEANUMYCINS AND USES THEREOF IN MEDICINE AND PLANT PROTECTION | KARS1, KLHL20, LSS | PDCD1LG2 4028/4885CD274 3921/4885MME 1482/4885 |
| US-12565666-B2 | Methods and compositions for modulating a genome | RPRD2, ERN2, TPR | PDCD1LG2 1836/4885CD274 2982/4885MME 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.